Literature DB >> 8703653

The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4'-hydroxylase activity in human liver microsomes.

K Kobayashi1, T Yamamoto, K Chiba, M Tani, T Ishizaki, Y Kuroiwa.   

Abstract

The inhibitory effects of four selective serotonin reuptake inhibitors (SSRIs), fluoxetine, sertraline, paroxetine and citalopram, and three metabolites (norfluoxetine, demethylcitalopram and didemethylcitalopram), on S-mephenytoin 4'-hydroxylation activities in human liver microsomes were studied. The 4'-hydroxylation of S-mephenytoin, a representative substrate toward CYP2C19, was competitively inhibited by all the SSRIs and their metabolites studied. The mean Ki values of fluoxetine, norfluoxetine, sertraline, paroxetine, citalopram, demethylcitalopram and didemethylcitalopram were 5.2, 1.1, 2.0, 7.5, 87.3, 55.8 and 7.7 microM, respectively. The findings suggest that some SSRIs and their metabolites with a low Ki value (e.g., fluoxetine, norfluoxetine) may reduce the clearance of drugs metabolized by this isoform of P450, thereby resulting in a possible drug-drug interaction, when administered simultaneously. In addition, SSRIs and their metabolites examined herein may be substrates toward CYP2C19.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8703653      PMCID: PMC1365195          DOI: 10.1111/j.1365-2125.1995.tb05793.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  32 in total

1.  The debrisoquine hydroxylation test predicts steady-state plasma levels of desipramine.

Authors:  L Bertilsson; A Aberg-Wistedt
Journal:  Br J Clin Pharmacol       Date:  1983-03       Impact factor: 4.335

2.  In vitro inhibition studies of two isozymes of human liver cytochrome P-450. Mephenytoin p-hydroxylase and sparteine monooxygenase.

Authors:  T Inaba; M Jurima; W A Mahon; W Kalow
Journal:  Drug Metab Dispos       Date:  1985 Jul-Aug       Impact factor: 3.922

3.  Lack of low Km diazepam N-demethylase in livers of poor metabolizers for S-mephenytoin 4'-hydroxylation.

Authors:  T Yasumori; Q H Li; Y Yamazoe; M Ueda; T Tsuzuki; R Kato
Journal:  Pharmacogenetics       Date:  1994-12

4.  E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation.

Authors:  B Mellström; L Bertilsson; J Säwe; H U Schulz; F Sjöqvist
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

5.  Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism.

Authors:  K Brøsen; R Klysner; L F Gram; S V Otton; P Bech; L Bertilsson
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

6.  Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.

Authors:  M Eichelbaum; N Spannbrucker; B Steincke; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

7.  High-performance liquid chromatographic determination of citalopram and four of its metabolites in plasma and urine samples from psychiatric patients.

Authors:  E Oyehaug; E T Ostensen; B Salvesen
Journal:  J Chromatogr       Date:  1984-06-08

8.  Characterization and inhibition of mephenytoin 4-hydroxylase activity in human liver microsomes.

Authors:  S D Hall; F P Guengerich; R A Branch; G R Wilkinson
Journal:  J Pharmacol Exp Ther       Date:  1987-01       Impact factor: 4.030

Review 9.  Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness.

Authors:  P Benfield; R C Heel; S P Lewis
Journal:  Drugs       Date:  1986-12       Impact factor: 9.546

10.  Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro.

Authors:  R Gugler; J C Jensen
Journal:  Gastroenterology       Date:  1985-12       Impact factor: 22.682

View more
  16 in total

1.  Evidence for involvement of polymorphic CYP2C19 and 2C9 in the N-demethylation of sertraline in human liver microsomes.

Authors:  Z H Xu; W Wang; X J Zhao; S L Huang; B Zhu; N He; Y Shu; Z Q Liu; H H Zhou
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

Review 2.  Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors.

Authors:  C L DeVane
Journal:  Cell Mol Neurobiol       Date:  1999-08       Impact factor: 5.046

3.  Selecting a Selective Serotonin Reuptake Inhibitor: Clinically Important Distinguishing Features.

Authors:  Patricia A. Marken; J Stuart Munro
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2000-12

4.  Inhibitory effects of antiarrhythmic drugs on phenacetin O-deethylation catalysed by human CYP1A2.

Authors:  K Kobayashi; M Nakajima; K Chiba; T Yamamoto; M Tani; T Ishizaki; Y Kuroiwa
Journal:  Br J Clin Pharmacol       Date:  1998-04       Impact factor: 4.335

5.  Are circulating metabolites important in drug-drug interactions?: Quantitative analysis of risk prediction and inhibitory potency.

Authors:  C K Yeung; Y Fujioka; H Hachad; R H Levy; N Isoherranen
Journal:  Clin Pharmacol Ther       Date:  2010-12-01       Impact factor: 6.875

6.  A genetic polymorphism of CYP2C19 is associated with susceptibility to biliary tract cancer.

Authors:  Yoshihiro Isomura; Yutaka Yamaji; Miki Ohta; Motoko Seto; Yoshinari Asaoka; Yasuo Tanaka; Takashi Sasaki; Yousuke Nakai; Naoki Sasahira; Hiroyuki Isayama; Minoru Tada; Haruhiko Yoshida; Takao Kawabe; Masao Omata; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2010-06-12       Impact factor: 7.527

Review 7.  Selective serotonin reuptake inhibitors for late-life depression: a comparative review.

Authors:  L K Solai; B H Mulsant; B G Pollock
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 8.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

9.  Contribution of human cytochrome p-450 isoforms to the metabolism of the simplest phenothiazine neuroleptic promazine.

Authors:  Jacek Wójcikowski; Lydiane Pichard-Garcia; Patrick Maurel; Władysława A Daniel
Journal:  Br J Pharmacol       Date:  2003-04       Impact factor: 8.739

10.  Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes.

Authors:  Karin Herrlin; Norio Yasui-Furukori; Gunnel Tybring; Jolanta Widén; Lars L Gustafsson; Leif Bertilsson
Journal:  Br J Clin Pharmacol       Date:  2003-10       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.